JP2008506789A5 - - Google Patents

Download PDF

Info

Publication number
JP2008506789A5
JP2008506789A5 JP2007533000A JP2007533000A JP2008506789A5 JP 2008506789 A5 JP2008506789 A5 JP 2008506789A5 JP 2007533000 A JP2007533000 A JP 2007533000A JP 2007533000 A JP2007533000 A JP 2007533000A JP 2008506789 A5 JP2008506789 A5 JP 2008506789A5
Authority
JP
Japan
Prior art keywords
misc
feature
phosphorothioate bond
oligonucleotide
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007533000A
Other languages
English (en)
Other versions
JP2008506789A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2005/004186 external-priority patent/WO2007026190A2/en
Publication of JP2008506789A publication Critical patent/JP2008506789A/ja
Publication of JP2008506789A5 publication Critical patent/JP2008506789A5/ja
Pending legal-status Critical Current

Links

Description

【０１０７】
【図１】インターフェロン-ガンマ（IFN-g）レベルに対する種々のアジュバントの効果を示す棒グラフである（皮下免疫）。
【図２】インターフェロン-ガンマ（IFN-g）レベルに対する種々のアジュバントの効果を示す棒グラフである（筋肉内免疫）。
【図３】インターフェロン-ガンマ（IFN-g）レベルに対する種々のオリゴヌクレオチドの効果を示す棒グラフである（皮下免疫）。
【図４】インターフェロン-ガンマ（IFN-g）レベルに対する種々のアジュバントの効果を示す棒グラフである（皮下免疫）。
【図５】抗HBsの総IgG力価に対する種々のアジュバントの効果を示すグラフである（皮下免疫）。
【図６】抗HBsAg特異的CTL応答に対する種々のアジュバントの効果を示すグラフである（皮下免疫）。
【図７】インターフェロン-ガンマ（IFN-g）レベルに対する、ミョウバンの存在下及び非存在下における種々のアジュバントの効果を示す棒グラフである。
【図８】インターフェロン-ガンマ（IFN-g）レベルに対する、ミョウバンの存在下及び非存在下における種々のアジュバントの効果を示す棒グラフである。
【図９】免疫刺激複合体とともに処方したオリゴヌクレオチドを用いたB16-OVAメラノーマに対するワクチン療法の結果を示す図表である。
【図１０】B16-OVAメラノーマの免疫療法の結果を示す図表である。
【図１１】ワクチン接種動物におけるOVA特異的CTLの誘発を示すグラフである。
【図１２】ワクチン接種動物の脾細胞によるOVA特異的IFN-ガンマの分泌を示すグラフである。
【図１３】OVA付加ペンタマーにより、脾細胞中のOVA特異的CD8+ T細胞を示すグラフである。
【図１４】子宮頸部細胞癌を誘発し、E6/E7ペプチド抗原でワクチン接種した動物の生存データを示すグラフである。
【図１５】子宮頸部細胞癌を誘発し、E6/E7ペプチド抗原でワクチン接種した動物の腫瘍体積データを示すグラフである。
【配列表】
SEQUENCE LISTING

<110> DAVIS, HEATHER L.
MCCLUSKIE, MICHAEL J.
DRANE, DEBORAH P.

<120> METHODS AND COMPOSITIONS FOR INDUCING ANTIGEN-SPECIFIC
IMMUNE RESPONSES

<130> 029860-0129

<140> 11/183,187
<141> 2005-07-18

<150> 60/589,259
<151> 2004-07-18

<160> 39

<170> PatentIn Ver. 3.3

<210> 1
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1
tcgtcgtttt gtcgttttgt cgtt 24


<210> 2
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 2
tgctgctttt gtgcttttgt gctt 24


<210> 3
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 3
gacgtc 6


<210> 4
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 4
agcgct 6


<210> 5
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 5
aacgtt 6


<210> 6
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> modified_base
<222> (3)..(27)
<223> This region may encompass 0-25 variable nucleotides

<220>
<221> modified_base
<222> (29)..(30)
<223> This region may encompass gt, gg, ga, or aa

<220>
<221> modified_base
<222> (33)..(34)
<223> This region may encompass tt, ct, or tc

<400> 6
tcnnnnnnnn nnnnnnnnnn nnnnnnntnn cgnn 34


<210> 7
<211> 7
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 7
tttttcg 7


<210> 8
<211> 3
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 8
tcg 3


<210> 9
<211> 4
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 9
ttcg 4


<210> 10
<211> 5
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 10
tttcg 5


<210> 11
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 11
ttttcg 6


<210> 12
<211> 4
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 12
tcgt 4


<210> 13
<211> 5
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 13
ttcgt 5


<210> 14
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 14
tttcgt 6


<210> 15
<211> 7
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 15
tcgtcgt 7


<210> 16
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 16
ccgcgcgg 8


<210> 17
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 17
cgacgttcgt cg 12


<210> 18
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 18
cggcgccgtg ccg 13


<210> 19
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 19
ccccccgggg gg 12


<210> 20
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 20
ggggggcccc cc 12


<210> 21
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 21
cccccggggg 10


<210> 22
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 22
gggggccccc 10


<210> 23
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> misc_feature
<222> (1)..(2)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (2)..(3)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (3)..(4)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (4)..(5)
<223> phosphorothioate bond


<220>
<221> misc_feature
<222> (5)..(6)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (6)..(7)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (7)..(8)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (8)..(9)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (9)..(10)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (10)..(11)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (11)..(12)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (12)..(13)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (13)..(14)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (14)..(15)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (15)..(16)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (16)..(17)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (17)..(18)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (18)..(19)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (19)..(20)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (20)..(21)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (21)..(22)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (22)..(23)
<223> phosphorothioate bond

<400> 23
tcgtcgacgt tcggcgcgcg ccg 23


<210> 24
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> misc_feature
<222> (1)..(2)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (2)..(3)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (3)..(4)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (4)..(5)
<223> phosphorothioate bond


<220>
<221> misc_feature
<222> (5)..(6)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (6)..(7)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (7)..(8)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (8)..(9)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (9)..(10)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (10)..(11)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (11)..(12)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (12)..(13)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (13)..(14)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (14)..(15)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (15)..(16)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (16)..(17)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (17)..(18)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (18)..(19)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (19)..(20)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (20)..(21)
<223> phosphorothioate bond

<400> 24
tcggacgttc ggcgcgcgcc g 21


<210> 25
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> misc_feature
<222> (1)..(2)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (2)..(3)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (3)..(4)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (4)..(5)
<223> phosphorothioate bond


<220>
<221> misc_feature
<222> (5)..(6)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (6)..(7)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (7)..(8)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (8)..(9)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (9)..(10)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (10)..(11)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (11)..(12)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (12)..(13)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (13)..(14)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (14)..(15)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (15)..(16)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (16)..(17)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (17)..(18)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (18)..(19)
<223> phosphorothioate bond

<400> 25
tcggacgttc ggcgcgccg 19


<210> 26
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> misc_feature
<222> (1)..(2)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (2)..(3)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (3)..(4)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (4)..(5)
<223> phosphodiester bond


<220>
<221> misc_feature
<222> (5)..(6)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (6)..(7)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (7)..(8)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (8)..(9)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (9)..(10)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (10)..(11)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (11)..(12)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (12)..(13)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (13)..(14)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (14)..(15)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (15)..(16)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (16)..(17)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (17)..(18)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (18)..(19)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (19)..(20)
<223> phosphorothioate bond

<400> 26
tcgcgtcgtt cggcgcgccg 20


<210> 27
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> misc_feature
<222> (1)..(2)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (2)..(3)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (3)..(4)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (4)..(5)
<223> phosphorothioate bond


<220>
<221> misc_feature
<222> (5)..(6)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (6)..(7)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (7)..(8)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (8)..(9)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (9)..(10)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (10)..(11)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (11)..(12)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (12)..(13)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (13)..(14)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (14)..(15)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (15)..(16)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (16)..(17)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (17)..(18)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (18)..(19)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (19)..(20)
<223> phosphorothioate bond

<400> 27
tcgacgttcg gcgcgcgccg 20


<210> 28
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> misc_feature
<222> (1)..(2)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (2)..(3)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (3)..(4)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (4)..(5)
<223> phosphorothioate bond


<220>
<221> misc_feature
<222> (5)..(6)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (6)..(7)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (7)..(8)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (8)..(9)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (9)..(10)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (10)..(11)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (11)..(12)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (12)..(13)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (13)..(14)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (14)..(15)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (15)..(16)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (16)..(17)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (17)..(18)
<223> phosphorothioate bond

<400> 28
tcgacgttcg gcgcgccg 18


<210> 29
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> misc_feature
<222> (1)..(2)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (2)..(3)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (3)..(4)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (4)..(5)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (5)..(6)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (6)..(7)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (7)..(8)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (8)..(9)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (9)..(10)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (10)..(11)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (11)..(12)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (12)..(13)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (13)..(14)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (14)..(15)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (15)..(16)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (16)..(17)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (17)..(18)
<223> phosphorothioate bond

<400> 29
tcgcgtcgtt cggcgccg 18


<210> 30
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> misc_feature
<222> (1)..(2)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (2)..(3)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (3)..(4)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (4)..(5)
<223> phosphodiester bond


<220>
<221> misc_feature
<222> (5)..(6)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (6)..(7)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (7)..(8)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (8)..(9)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (9)..(10)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (10)..(11)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (11)..(12)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (12)..(13)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (13)..(14)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (14)..(15)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (15)..(16)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (16)..(17)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (17)..(18)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (18)..(19)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (19)..(20)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (20)..(21)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (21)..(22)
<223> phosphorothioate bond

<400> 30
tcgcgacgtt cggcgcgcgc cg 22


<210> 31
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> misc_feature
<222> (1)..(2)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (2)..(3)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (3)..(4)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (4)..(5)
<223> phosphodiester bond


<220>
<221> misc_feature
<222> (5)..(6)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (6)..(7)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (7)..(8)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (8)..(9)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (9)..(10)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (10)..(11)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (11)..(12)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (12)..(13)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (13)..(14)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (14)..(15)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (15)..(16)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (16)..(17)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (17)..(18)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (18)..(19)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (19)..(20)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (20)..(21)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (21)..(22)
<223> phosphorothioate bond

<400> 31
tcgcgtcgtt cggcgcgcgc cg 22


<210> 32
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> misc_feature
<222> (1)..(2)
<223> phosphorothioate bond

<220>
<221> modified_base
<222> (2)..(2)
<223> guanine or modified guanine base

<220>
<221> misc_feature
<222> (2)..(3)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (3)..(4)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (4)..(5)
<223> phosphorothioate bond

<220>
<221> modified_base
<222> (5)..(5)
<223> guanine or modified guanine base

<220>
<221> misc_feature
<222> (5)..(6)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (6)..(7)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (7)..(8)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (8)..(9)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (9)..(10)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (10)..(11)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (11)..(12)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (12)..(13)
<223> phosphorothioate bond

<220>
<221> modified_base
<222> (13)..(13)
<223> guanine or modified guanine base

<220>
<221> misc_feature
<222> (13)..(14)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (14)..(15)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (15)..(16)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (16)..(17)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (17)..(18)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (18)..(19)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (19)..(20)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (20)..(21)
<223> phosphorothioate bond

<220>
<221> modified_base
<222> (21)..(21)
<223> guanine or modified guanine base

<220>
<221> misc_feature
<222> (21)..(22)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (22)..(23)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (23)..(24)
<223> phosphorothioate bond

<400> 32
tngtngtttt gtngttttgt ngtt 24


<210> 33
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> misc_feature
<222> (1)..(2)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (2)..(3)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (3)..(4)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (4)..(5)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (5)..(6)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (6)..(7)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (7)..(8)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (8)..(9)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (9)..(10)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (10)..(11)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (11)..(12)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (12)..(13)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (13)..(14)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (14)..(15)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (15)..(16)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (16)..(17)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (17)..(18)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (18)..(19)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (19)..(20)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (20)..(21)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (21)..(22)
<223> phosphodiester bond

<220>
<221> misc_feature
<222> (22)..(23)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (23)..(24)
<223> phosphorothioate bond

<400> 33
tgctgctttt gtgcttttgt gctt 24


<210> 34
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> misc_feature
<222> (1)..(2)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (2)..(3)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (3)..(4)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (4)..(5)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (5)..(6)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (6)..(7)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (7)..(8)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (8)..(9)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (9)..(10)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (10)..(11)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (11)..(12)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (12)..(13)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (13)..(14)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (14)..(15)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (15)..(16)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (16)..(17)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (17)..(18)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (18)..(19)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (19)..(20)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (20)..(21)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (21)..(22)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (22)..(23)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (23)..(24)
<223> phosphorothioate bond

<400> 34
gtgctccttt gttgttctgt gttt 24


<210> 35
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> misc_feature
<222> (1)..(2)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (2)..(3)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (3)..(4)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (4)..(5)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (5)..(6)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (6)..(7)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (7)..(8)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (8)..(9)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (9)..(10)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (10)..(11)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (11)..(12)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (12)..(13)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (13)..(14)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (14)..(15)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (15)..(16)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (16)..(17)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (17)..(18)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (18)..(19)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (19)..(20)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (20)..(21)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (21)..(22)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (22)..(23)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (23)..(24)
<223> phosphorothioate bond

<400> 35
aagcacaaaa gcacaaaagc agca 24


<210> 36
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> misc_feature
<222> (1)..(2)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (2)..(3)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (3)..(4)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (4)..(5)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (5)..(6)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (6)..(7)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (7)..(8)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (8)..(9)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (9)..(10)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (10)..(11)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (11)..(12)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (12)..(13)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (13)..(14)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (14)..(15)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (15)..(16)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (16)..(17)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (17)..(18)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (18)..(19)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (19)..(20)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (20)..(21)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (21)..(22)
<223> phosphorothioate bond

<400> 36
tgctggcctc ctggcctggt gc 22


<210> 37
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> misc_feature
<222> (1)..(2)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (2)..(3)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (3)..(4)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (4)..(5)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (5)..(6)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (6)..(7)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (7)..(8)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (8)..(9)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (9)..(10)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (10)..(11)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (11)..(12)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (12)..(13)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (13)..(14)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (14)..(15)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (15)..(16)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (16)..(17)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (17)..(18)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (18)..(19)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (19)..(20)
<223> phosphorothioate bond

<400> 37
tgtgcttttt tttttttttt 20


<210> 38
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> misc_feature
<222> (1)..(2)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (2)..(3)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (3)..(4)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (4)..(5)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (5)..(6)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (6)..(7)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (7)..(8)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (8)..(9)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (9)..(10)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (10)..(11)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (11)..(12)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (12)..(13)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (13)..(14)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (14)..(15)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (15)..(16)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (16)..(17)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (17)..(18)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (18)..(19)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (19)..(20)
<223> phosphorothioate bond

<400> 38
tccaggactt ctctcaggtt 20


<210> 39
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>
<221> misc_feature
<222> (1)..(2)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (2)..(3)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (3)..(4)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (4)..(5)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (5)..(6)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (6)..(7)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (7)..(8)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (8)..(9)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (9)..(10)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (10)..(11)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (11)..(12)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (12)..(13)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (13)..(14)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (14)..(15)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (15)..(16)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (16)..(17)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (17)..(18)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (18)..(19)
<223> phosphorothioate bond

<220>
<221> misc_feature
<222> (19)..(20)
<223> phosphorothioate bond

<400> 39
gccaggacac ctcacaggat 20

Claims (31)

  1. （a）オリゴヌクレオチド成分、（b）免疫刺激複合体成分及び（c）抗原成分を含む医薬であって、前記医薬が、脊椎動物対象に投与されたときインターフェロン-ガンマ応答を誘発する、前記医薬。
  2. 前記医薬によって誘発されるインターフェロン-ガンマ応答が、（a）前記オリゴヌクレオチド成分及び（b）前記抗原成分を含むが免疫刺激複合体を含まない第二の医薬によって誘発されるインターフェロン-ガンマ応答よりも強い、請求項1の医薬。
  3. 前記オリゴヌクレオチドが1つ又は2つ以上のCpGモチーフを含む、請求項1の医薬。
  4. 前記オリゴヌクレオチドが、AクラスCpGオリゴヌクレオチド、BクラスCpGオリゴヌクレオチド、又はCクラスCpGオリゴヌクレオチドである、請求項3の医薬。
  5. 前記オリゴヌクレオチドが、1つ又は2つ以上の非CpGモチーフを含む、請求項1の医薬。
  6. 前記オリゴヌクレオチドが、T-富裕オリゴヌクレオチド、ポリ-Tオリゴヌクレオチド又はポリ-Gオリゴヌクレオチドである、請求項5の医薬。
  7. 前記オリゴヌクレオチドが、少なくとも1つのホスホロチオエートヌクレオチド間架橋を含む、請求項5の医薬。
  8. 前記オリゴヌクレオチドが不活性なオリゴヌクレオチドである、請求項1の医薬。
  9. 前記オリゴヌクレオチドがパリンドロームを含む、請求項1の医薬。
  10. 前記オリゴヌクレオチドが前記免疫刺激複合体に取り込まれる、請求項1の医薬。
  11. 前記免疫刺激複合体がサポニン及びステロールを含む、請求項1の医薬。
  12. 前記抗原が、癌抗原、微生物抗原及びアレルゲンからなる群より選択される、請求項1の医薬。
  13. 前記オリゴヌクレオチドが不活性なオリゴヌクレオチドであり、前記免疫刺激複合体がサポニン及びステロールを含み、さらに前記抗原が癌抗原である、請求項1の医薬。
  14. 脊椎動物対象でインターフェロン-ガンマ応答を誘発するための、（i）オリゴヌクレオチド成分、（ii）免疫刺激複合体成分及び（iii）抗原成分を含む医薬を製造するための、成分（i）、（ii）及び（iii）の使用。
  15. 前記医薬によって誘発されるインターフェロン-ガンマ応答が、（a）前記オリゴヌクレオチド成分及び（b）前記抗原成分を含むが免疫刺激複合体を含まない第二の医薬によって誘発されるインターフェロン-ガンマ応答よりも強い、請求項14の使用。
  16. さらにインターフェロン-ガンマ応答を測定する工程を含む、請求項14の使用。
  17. 成分（i）、（ii）及び（iii）が一緒に投与される、請求項14の使用。
  18. 成分（i）及び（iii）が別々に投与される、請求項14の使用。
  19. 前記オリゴヌクレオチドが1つ又は2つ以上のCpGモチーフを含む、請求項14の使用。
  20. 前記オリゴヌクレオチドが、AクラスCpGオリゴヌクレオチド、BクラスCpGオリゴヌクレオチド、又はCクラスCpGオリゴヌクレオチドである、請求項19の使用。
  21. 前記オリゴヌクレオチドが、1つ又は2つ以上の非CpGモチーフを含む、請求項14の使用。
  22. 前記オリゴヌクレオチドが、T-富裕オリゴヌクレオチド、ポリ-Tオリゴヌクレオチド又はポリ-Gオリゴヌクレオチドである、請求項21の使用。
  23. 前記オリゴヌクレオチドが、少なくとも1つのホスホロチオエートヌクレオチド間架橋を含む、請求項21の使用。
  24. 前記オリゴヌクレオチドが不活性なオリゴヌクレオチドである、請求項14の使用。
  25. 前記オリゴヌクレオチドがパリンドロームを含む、請求項14の使用。
  26. 前記オリゴヌクレオチドが前記免疫刺激複合体に取り込まれる、請求項14の使用。
  27. 前記免疫刺激複合体がサポニン及びステロールを含む、請求項14の使用。
  28. 前記抗原が、癌抗原、微生物抗原及びアレルゲンからなる群より選択される、請求項14の使用。
  29. 前記オリゴヌクレオチドが不活性なオリゴヌクレオチドであり、前記免疫刺激複合体がサポニン及びステロールを含み、さらに前記抗原が癌抗原である、請求項14の使用。
  30. 前記医薬が筋肉内又は皮下に投与される、請求項14の使用。
  31. 前記医薬が粘膜に投与される、請求項14の使用。
JP2007533000A 2004-07-18 2005-07-18 インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物 Pending JP2008506789A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58925904P 2004-07-18 2004-07-18
PCT/IB2005/004186 WO2007026190A2 (en) 2004-07-18 2005-07-18 Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses

Publications (2)

Publication Number Publication Date
JP2008506789A JP2008506789A (ja) 2008-03-06
JP2008506789A5 true JP2008506789A5 (ja) 2008-08-21

Family

ID=37600857

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007533000A Pending JP2008506789A (ja) 2004-07-18 2005-07-18 インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物

Country Status (8)

Country Link
US (1) US20060287263A1 (ja)
EP (2) EP2484374A1 (ja)
JP (1) JP2008506789A (ja)
KR (2) KR20100018029A (ja)
AU (2) AU2005335104C1 (ja)
CA (1) CA2572427A1 (ja)
NZ (1) NZ553244A (ja)
WO (1) WO2007026190A2 (ja)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0879284B1 (en) * 1996-01-30 2009-07-29 The Regents of The University of California Gene expression vectors which generate an antigen specific immune response and methods of using the same
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1733735B1 (en) 1998-05-22 2017-03-22 Ottawa Hospital Research Institute Methods and products for inducing mucosal immunity
EP2204186B1 (en) 1999-02-17 2016-04-06 CSL Limited Immunogenic complexes and methods relating thereto
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
WO2001037869A1 (en) * 1999-11-19 2001-05-31 Csl Limited Vaccine compositions
SG177000A1 (en) 2001-08-17 2012-01-30 Coley Pharm Gmbh Combination motif immune stimulatory oligonucleotides with improved activity
EP1467755A1 (en) 2001-12-21 2004-10-20 Antigenics Inc. Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
EP3006043B1 (en) 2002-04-04 2019-05-29 Zoetis Belgium S.A. Immunostimulatory g,u-containing oligoribonucleotides
KR20050009697A (ko) * 2002-04-22 2005-01-25 바이오니취 라이프 사이언시즈 인코포레이티드 올리고뉴클레오티드 조성물 및 면역 반응 조절시 이의 용도
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
ZA200503511B (en) 2002-10-29 2006-10-25 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
US7956043B2 (en) 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use
CN101454451A (zh) 2003-10-30 2009-06-10 科勒制药有限公司 具有增强免疫刺激能力的c类寡核苷酸类似物
US20070190072A1 (en) * 2004-09-30 2007-08-16 Csl Limited Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus adjuvant
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
KR20080072934A (ko) 2005-11-25 2008-08-07 콜리 파마슈티칼 게엠베하 면역자극성 올리고리보뉴클레오티드
EP1991678B2 (en) * 2006-02-15 2020-07-15 Rechtsanwalt Thomas Beck Compositions and methods for oligonucleotide formulations
EA014757B1 (ru) * 2006-02-28 2011-02-28 Вэксарт, Инк. Химерный аденовирусный вектор, иммуногенная композиция на его основе, способ индукции иммуного ответа с его помощью и выделенная нуклеиновая кислота
MX2009003398A (es) 2006-09-27 2009-08-12 Coley Pharm Gmbh Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
WO2008063129A1 (en) * 2006-11-20 2008-05-29 Duecom Use of lipid containing particles comprising quillaja saponins for the treatment of cancer
AP2707A (en) * 2007-08-27 2013-07-29 Siga Technologies Inc Antiviral drugs for treatment of arenavirus infection
CN101820904A (zh) * 2007-10-12 2010-09-01 Csl有限公司 引起针对大流行性流感病毒的免疫应答的方法
TWI351288B (en) * 2008-07-04 2011-11-01 Univ Nat Pingtung Sci & Tech Cpg dna adjuvant in avian vaccines
SG10201400388QA (en) 2008-12-09 2014-05-29 Pfizer Vaccines Llc IgE CH3 peptide vaccine
CA3033133C (en) 2009-03-25 2021-11-09 The Board Of Regents Of The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
EP2424562B1 (en) 2009-04-30 2015-10-07 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
SG177637A1 (en) 2009-07-30 2012-03-29 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
SG10201401516XA (en) 2009-09-03 2014-10-30 Pfizer Vaccines Llc Pcsk9 vaccine
NZ629256A (en) 2009-12-22 2016-02-26 Celldex Therapeutics Inc Vaccine compositions
DK2563316T3 (da) * 2010-04-30 2019-05-13 Allovate Llc Tandpasta til allergisk desensibilisering via mundslimhinder
US8895017B2 (en) 2010-06-07 2014-11-25 Pfizer Inc. HER-2 peptides and vaccines
EP2942061A3 (en) 2010-06-07 2016-01-13 Pfizer Vaccines LLC Ige ch3 peptide vaccine
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
TWI454478B (zh) * 2011-05-13 2014-10-01 Academia Sinica 類鐸受體-２ 增效劑及其用於刺激免疫反應之用途
CA2845884A1 (en) 2011-08-22 2013-02-28 Cangene Corporation Clostridium difficile antibodies
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
BR112016006064B1 (pt) 2013-09-19 2020-07-07 Allovate, Llc kit para terapia da mucosa oral, método para formular uma composição de dentífrico, e, uso de um kit para terapia da mucosa oral
MX371454B (es) 2014-01-21 2020-01-29 Pfizer Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos.
RU2743793C1 (ru) 2014-01-21 2021-02-26 Пфайзер Инк. Капсульные полисахариды Streptococcus pneumoniae и их конъюгаты
PE20212335A1 (es) 2014-01-21 2021-12-16 Pfizer Composiciones inmunogenicas que comprenden antigenos sacaridos capsulares conjugados y usos de los mismos
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
EP3107567A4 (en) 2014-02-19 2017-10-25 Cangene Corporation Methods of modulating an immune response
WO2015157629A2 (en) 2014-04-10 2015-10-15 Obi Pharma Inc. Antibodies, pharmaceutical compositions and uses thereof
US10286065B2 (en) 2014-09-19 2019-05-14 Board Of Regents, The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
PT3244917T (pt) 2015-01-15 2023-05-31 Pfizer Composições imunogénicas para utilização em vacinas pneumocócicas
WO2016193405A1 (en) 2015-06-03 2016-12-08 Affiris Ag Il-23-p19 vaccines
EP3319988A1 (en) 2015-07-07 2018-05-16 Affiris AG Vaccines for the treatment and prevention of ige mediated diseases
KR102225282B1 (ko) 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
CN116063481A (zh) 2015-09-04 2023-05-05 普里玛托普医疗股份有限公司 人源化抗-cd40抗体及其用途
WO2017041027A1 (en) 2015-09-04 2017-03-09 Obi Pharma, Inc. Glycan arrays and method of use
EP3377098A1 (en) 2015-11-20 2018-09-26 Pfizer Inc Immunogenic compositions for use in pneumococcal vaccines
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
KR20180121786A (ko) 2016-03-29 2018-11-08 오비아이 파머 인코퍼레이티드 항체, 제약 조성물 및 방법
KR20230110820A (ko) 2016-04-22 2023-07-25 오비아이 파머 인코퍼레이티드 글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에의한 암 면역요법
CN110072545A (zh) 2016-07-27 2019-07-30 台湾浩鼎生技股份有限公司 免疫原性/治疗性聚糖组合物及其用途
WO2018018170A1 (es) * 2016-07-29 2018-02-01 Saponin Research Center S.A. Uso de extractos de quillaja saponaria para la prevención y control de infecciones bacterianas en peces
KR102528998B1 (ko) 2016-07-29 2023-05-03 오비아이 파머 인코퍼레이티드 인간 항체, 제약 조성물 및 방법
JP2019535731A (ja) 2016-11-21 2019-12-12 オービーアイ ファーマ，インコーポレイテッド コンジュゲートさせた生物学的分子、医薬組成物及び方法
WO2018134693A1 (en) 2017-01-20 2018-07-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
US11203645B2 (en) 2018-06-27 2021-12-21 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3120922A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
WO2020208502A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP4051696A1 (en) 2019-11-01 2022-09-07 Pfizer Inc. Escherichia coli compositions and methods thereof
MX2022010350A (es) 2020-02-23 2022-09-19 Pfizer Composiciones de esquerichia coli y sus metodos.
JP2023546615A (ja) 2020-10-27 2023-11-06 ファイザー・インク 大腸菌組成物およびその方法
WO2022097010A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
WO2022147373A1 (en) 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
US20220387576A1 (en) 2021-05-28 2022-12-08 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PE20240090A1 (es) 2021-05-28 2024-01-16 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN115177718B (zh) * 2022-05-25 2023-02-17 中国水产科学研究院南海水产研究所 花鲈干扰素IFN-γ及其受体抗病毒组合物和应用

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
DE3280400D1 (de) 1981-10-23 1992-06-04 Molecular Biosystems Inc Oligonukleotides heilmittel und dessen herstellungsverfahren.
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
DE3775783D1 (de) 1986-01-14 1992-02-20 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US5178860A (en) 1989-09-01 1993-01-12 Coopers Animal Health Limited Adjuvant complexes and vaccine made therefrom
US4981684A (en) * 1989-10-24 1991-01-01 Coopers Animal Health Limited Formation of adjuvant complexes
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
WO1992016192A1 (en) 1991-03-15 1992-10-01 Amgen Inc. Pulmonary administration of granulocyte colony stimulating factor
DE4321946A1 (de) 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
US5859231A (en) 1993-09-03 1999-01-12 Duke University Synthesis of oligonucleotides with boranophosphonate linkages
WO1995026204A1 (en) * 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US5658738A (en) 1994-05-31 1997-08-19 Becton Dickinson And Company Bi-directional oligonucleotides that bind thrombin
US20030050263A1 (en) * 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CA2194761C (en) 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US7935675B1 (en) * 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6160109A (en) 1995-10-20 2000-12-12 Isis Pharmaceuticals, Inc. Preparation of phosphorothioate and boranophosphate oligomers
US5780448A (en) * 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
SE9600648D0 (sv) * 1996-02-21 1996-02-21 Bror Morein Receptorbimdande enhet
ATE292980T1 (de) * 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
EP0855184A1 (en) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
WO1998037919A1 (en) * 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
ATE408422T1 (de) * 1997-07-03 2008-10-15 Donald E Macfarlane Methode zur hemmung immunstimulatorischer mit dna assoziierter antworten
ES2284247T3 (es) 1998-04-03 2007-11-01 University Of Iowa Research Foundation Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos.
IL139646A0 (en) * 1998-05-14 2002-02-10 Coley Pharm Group Inc Methods for regulating hematopoiesis using cpg-oligonucleotides
EP1733735B1 (en) * 1998-05-22 2017-03-22 Ottawa Hospital Research Institute Methods and products for inducing mucosal immunity
WO2000006588A1 (en) 1998-07-27 2000-02-10 University Of Iowa Research Foundation STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS
GB9817052D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
CA2341338A1 (en) 1998-09-03 2000-03-16 Coley Pharmaceutical Gmbh G-motif oligonucleotides and uses thereof
US20020065236A1 (en) * 1998-09-09 2002-05-30 Yew Nelson S. CpG reduced plasmids and viral vectors
AUPP807399A0 (en) * 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
US6207819B1 (en) 1999-02-12 2001-03-27 Isis Pharmaceuticals, Inc. Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
EP2204186B1 (en) * 1999-02-17 2016-04-06 CSL Limited Immunogenic complexes and methods relating thereto
BRPI0010612B8 (pt) * 1999-04-19 2021-05-25 Smithkline Beecham Biologicals S A vacinas
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
AP1775A (en) * 1999-09-25 2007-08-28 Univ Iowa Res Found Immunostimulatory nucleic acids.
MXPA02003059A (es) 1999-09-27 2002-09-30 Univ Iowa Res Found Metodos relacionados con interferon inducido por acido nucleico inmunoestabilizador.
JP4659937B2 (ja) * 1999-11-19 2011-03-30 ナノキャリア株式会社 コア−シェル構造のポリイオンコンプレックスミセル
WO2001037869A1 (en) * 1999-11-19 2001-05-31 Csl Limited Vaccine compositions
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20040131628A1 (en) * 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
US6339630B1 (en) * 2000-05-18 2002-01-15 The United States Of America As Represented By The United States Department Of Energy Sealed drive screw operator
WO2001097843A2 (en) * 2000-06-22 2001-12-27 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
US20020091097A1 (en) * 2000-09-07 2002-07-11 Bratzler Robert L. Nucleic acids for the prevention and treatment of sexually transmitted diseases
WO2002022809A2 (en) 2000-09-15 2002-03-21 Coley Pharmaceutical Gmbh PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
FR2814958B1 (fr) * 2000-10-06 2003-03-07 Aventis Pasteur Composition vaccinale
GB0025577D0 (en) * 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
AU4433702A (en) * 2000-10-18 2002-04-29 Smithkline Beecham Biolog Vaccines
EP1985702A3 (en) * 2000-12-08 2010-08-18 Coley Pharmaceutical GmbH CPG-like nucleic acids and methods of use thereof
AU2002248185A1 (en) * 2000-12-14 2002-07-16 Coley Pharmaceutical Group, Inc. Inhibition of angiogenesis by nucleic acids
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
JP2003031477A (ja) 2001-07-17 2003-01-31 Hitachi Ltd 半導体装置の製造方法およびシステム
AU2002318944A1 (en) * 2001-08-01 2003-02-17 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
SG177000A1 (en) * 2001-08-17 2012-01-30 Coley Pharm Gmbh Combination motif immune stimulatory oligonucleotides with improved activity
BR0213097A (pt) * 2001-10-05 2005-02-01 Coley Pharm Gmbh Agonistas e antagonistas sinalizadores do receptor 3 similar a toll
US20030139364A1 (en) * 2001-10-12 2003-07-24 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
EP3006043B1 (en) * 2002-04-04 2019-05-29 Zoetis Belgium S.A. Immunostimulatory g,u-containing oligoribonucleotides
US20040009949A1 (en) * 2002-06-05 2004-01-15 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) * 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
WO2004007743A2 (en) 2002-07-17 2004-01-22 Coley Pharmaceutical Gmbh Use of cpg nucleic acids in prion-disease
WO2004039950A2 (en) * 2002-10-25 2004-05-13 Chiron Corporation Activation of hcv-specific cells
ZA200503511B (en) * 2002-10-29 2006-10-25 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
BRPI0411514A (pt) * 2003-06-20 2006-08-01 Coley Pharm Gmbh antagonistas de receptor toll-like de molécula pequena
AU2005243250A1 (en) * 2004-04-02 2005-11-24 Coley Pharmaceutical Gmbh Immunostimulatory nucleic acids for inducing IL-10 responses
CA2574090A1 (en) * 2004-07-18 2006-12-21 Coley Pharmaceutical Group, Ltd. Methods and compositions for inducing innate immune responses
US20070190072A1 (en) * 2004-09-30 2007-08-16 Csl Limited Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus adjuvant
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
US7380084B2 (en) * 2005-09-30 2008-05-27 Intel Corporation Dynamic detection of block boundaries on memory reads
KR20080072934A (ko) * 2005-11-25 2008-08-07 콜리 파마슈티칼 게엠베하 면역자극성 올리고리보뉴클레오티드
US9501570B2 (en) 2014-07-14 2016-11-22 Verizon Patent And Licensing Inc. Dynamic routing system
US9719791B2 (en) 2014-12-10 2017-08-01 Mapquest, Inc. Computerized systems and methods for providing travel information and/or content to users

Similar Documents

Publication Publication Date Title
JP2008506789A5 (ja)
Mbow et al. New adjuvants for human vaccines
Shi et al. Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity
RU2322257C2 (ru) КОМПОЗИЦИИ, СОДЕРЖАЩИЕ CpG-ОЛИГОНУКЛЕОТИДЫ И ВИРУСОПОДОБНЫЕ ЧАСТИЦЫ, ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ АДЪЮВАНТОВ
Joseph et al. Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines
KR101528021B1 (ko) 콜레스테롤 및 ｃｐｇ를 단독 아주반트－담체 분자로서 포함하는 백신
Montomoli et al. Current adjuvants and new perspectives in vaccine formulation
Eastcott et al. Oligonucleotide containing CpG motifs enhances immune response to mucosally or systemically administered tetanus toxoid
WO2002034205A3 (en) Using heat shock proteins to increase immune response
ATE494910T1 (de) Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort
JP2005507388A5 (ja)
WO2000057917A3 (en) Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
JP2004530629A (ja) 免疫刺激ｒｎａ／ｄｎａハイブリッド分子
JP2008000001A (ja) 免疫刺激オリゴヌクレオチドおよびその医薬用途
Sun et al. Enhancement of HIV-1 DNA vaccine immunogenicity by BCG-PSN, a novel adjuvant
WO2006081323A3 (en) Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin
Moyle Progress in Vaccine Development: Vaccines
WO2003090687A3 (en) Using heat shock proteins to increase immune response
Wang et al. Adjuvant synergy in the response to hepatitis B vaccines
Mariotti et al. Immunogenicity of anti-Haemophilus influenzae type b CRM197 conjugate following mucosal vaccination with oligodeoxynucleotide containing immunostimulatory sequences as adjuvant
Pihlgren et al. CpG-motifs enhance initial and sustained primary tetanus-specific antibody secreting cell responses in spleen and bone marrow, but are more effective in adult than in neonatal mice
AU2003229435A8 (en) Pathogen vaccines and methods for using the same
JP2005525414A5 (ja)
PT1227840E (pt) Vacinas genéticas adjuvadas
EP1490100B1 (en) Combined dna/protein vaccine compositions